The 6 most recent market catalysts affecting $ATTO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 92
Attovia Therapeutics Q2 EPS $(4.88) Misses $(4.62) Estimate, Sales $450.000K
Attovia Therapeutics announced its Q2 earnings, reporting a loss of $(4.88) per share, which was worse than the analyst consensus estimate of $(4.62). This represents a 31.54% incr…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 75
Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30
Citigroup analyst Yigal Nochomovitz has initiated coverage on Attovia Therapeutics (ATTO) with a 'Buy' rating and a $30 price target. This is a significant event for a relatively n…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 55
LifeSci Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45
LifeSci Capital has initiated coverage on Attovia Therapeutics (ATTO) with an 'Outperform' rating and a $45 price target. This event is significant as new analyst coverage, especia…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 65
Leerink Partners Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $52
Leerink Partners, a prominent investment bank, has initiated coverage on Attovia Therapeutics (ATTO) with a positive 'Outperform' rating and a $52 price target. This event is signi…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 65
RBC Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45
RBC Capital's initiation of coverage on Attovia Therapeutics with an Outperform rating and a $45 price target is a positive development for the company. Analyst coverage often brin…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 65
Morgan Stanley Initiates Coverage On Attovia Therapeutics with Overweight Rating, Announces Price Target of $39
Morgan Stanley analyst Judah Frommer initiated coverage on Attovia Therapeutics (ATTO) with an 'Overweight' rating and a $39 price target. This event is significant because new ana…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.